Free Trial
→ Elon just declared war on your phone (From Stansberry Research) (Ad)tc pixel Free ACHV Stock Alerts

Achieve Life Sciences (ACHV) Financials

Achieve Life Sciences logo
$7.41 +0.22 (+3.06%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$7.32 -0.09 (-1.28%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Achieve Life Sciences

Annual Income Statements for Achieve Life Sciences

This table shows Achieve Life Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -17 -1.23 -11 -13 -16 -15 -33 -42 -30 -40 -55
Consolidated Net Income / (Loss)		 -17 -1.23 -11 -13 -16 -15 -33 -42 -30 -40 -55
Net Income / (Loss) Continuing Operations		 -17 -1.23 -11 -13 -16 -15 -33 -42 -30 -40 -54
Total Pre-Tax Income 		-17 -1.74 -14 -13 -16 -15 -33 -42 -30 -40 -55
Total Operating Income		 -19 -1.71 -6.63 -13 -17 -15 -33 -41 -28 -40 -55
Total Gross Profit		 18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 37 1.71 6.63 13 17 15 33 41 28 40 55
Selling, General & Admin Expense		 12 1.43 3.53 6.95 6.85 7.87 9.13 11 11 16 32
Research & Development Expense		 25 0.29 3.10 5.87 9.67 6.88 24 30 16 23 23
Total Other Income / (Expense), net		 1.95 -0.02 -7.00 0.13 0.13 0.02 -0.06 -1.55 -2.04 -0.14 0.23
Interest Expense		 - - - - - 0.00 0.00 1.79 2.85 2.46 0.82
Interest & Investment Income		 0.12 - 0.02 0.17 0.17 0.07 0.02 0.20 0.83 2.36 1.50
Other Income / (Expense), net		 1.83 -0.02 -7.02 -0.05 -0.04 -0.05 -0.08 0.04 -0.01 -0.03 -0.44
Other Gains / (Losses), net		 - - - - 0.13 - -0.06 - - - 0.23
Basic Earnings per Share		 ($0.64) ($581.25) ($22.07) ($72.29) ($39.76) ($5.42) ($4.08) ($4.00) ($1.50) ($1.24) ($1.25)
Weighted Average Basic Shares Outstanding		 26.15M 2.12K 479.44K 175.51K 412.32K 2.72M 8.12M 10.59M 19.83M 32.07M 43.59M
Diluted Earnings per Share		 ($0.64) ($581.25) ($22.07) ($72.29) ($39.76) ($5.42) ($4.08) ($4.00) ($1.50) ($1.24) ($1.25)
Weighted Average Diluted Shares Outstanding		 26.15M 2.12K 479.44K 175.51K 412.32K 2.72M 8.12M 10.59M 19.83M 32.07M 43.59M
Weighted Average Basic & Diluted Shares Outstanding		 26.15M 2.12K 479.44K 175.51K 412.32K 2.72M 8.12M 17.93M 34.25M 34.69M 53.24M

Quarterly Income Statements for Achieve Life Sciences

This table shows Achieve Life Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -5.48 -6.49 -8.46 -13 -12 -13 -13 -14 -15 -10 -75
Consolidated Net Income / (Loss)		 -5.48 -6.49 -8.46 -13 -12 -13 -13 -14 -15 -10 -75
Net Income / (Loss) Continuing Operations		 -5.48 -6.49 -8.49 -13 -12 -13 -13 -14 -14 -10 -75
Total Pre-Tax Income 		-5.48 -6.49 -8.46 -13 -12 -13 -13 -14 -15 -10 -75
Total Operating Income		 -4.91 -6.03 -8.43 -12 -13 -13 -13 -15 -15 -10 -18
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 4.91 6.03 8.43 12 13 13 13 15 15 10 18
Selling, General & Admin Expense		 2.27 3.18 3.32 4.86 4.89 5.80 5.86 9.37 11 7.17 15
Research & Development Expense		 2.11 2.80 5.11 7.61 7.30 7.10 6.71 5.32 3.87 3.29 3.81
Total Other Income / (Expense), net		 -0.56 -0.46 -0.03 -0.05 0.40 0.07 -0.06 0.36 -0.13 0.30 -56
Interest Expense		 0.79 0.81 0.80 0.65 0.20 0.19 0.19 0.19 0.25 0.27 0.28
Interest & Investment Income		 0.21 0.37 0.83 0.67 0.48 0.32 0.19 0.55 0.43 0.30 1.48
Other Income / (Expense), net		 0.02 -0.02 -0.06 -0.07 0.11 -0.07 -0.06 -0.01 -0.31 0.27 -58
Basic Earnings per Share		 ($0.23) ($0.26) ($0.25) ($0.36) ($0.37) ($0.37) ($0.37) ($0.28) ($0.23) ($0.19) ($0.80)
Weighted Average Basic Shares Outstanding		 19.83M 25.05M 34.32M 34.36M 32.07M 34.69M 34.69M 51.02M 43.59M 53.38M 93.51M
Diluted Earnings per Share		 ($0.23) ($0.26) ($0.25) ($0.36) ($0.37) ($0.37) ($0.37) ($0.28) ($0.23) ($0.19) ($0.80)
Weighted Average Diluted Shares Outstanding		 19.83M 25.05M 34.32M 34.36M 32.07M 34.69M 34.69M 51.02M 43.59M 53.38M 93.51M
Weighted Average Basic & Diluted Shares Outstanding		 34.25M 34.34M 34.34M 34.39M 34.69M 34.69M 51.10M 53.23M 53.24M 102.66M 102.90M

Annual Cash Flow Statements for Achieve Life Sciences

This table details how cash moves in and out of Achieve Life Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.06 -0.05 5.54 4.01 7.15 19 7.17 -18 -9.23 -2.82 8.18
Net Cash From Operating Activities		 -0.35 -0.20 -9.11 -11 -15 -13 -29 -38 -24 -30 -49
Net Cash From Continuing Operating Activities		 -0.35 -0.20 -9.11 -11 -15 -14 -29 -38 -24 -30 -49
Net Income / (Loss) Continuing Operations		 -0.83 -1.23 -11 -13 -16 -15 -33 -42 -30 -40 -55
Consolidated Net Income / (Loss)		 -0.83 -1.23 -11 -13 -16 -15 -33 -42 -30 -40 -55
Depreciation Expense		 - - 0.06 0.06 0.03 0.26 0.25 0.24 0.23 0.23 0.23
Amortization Expense		 0.14 0.22 0.22 0.22 0.22 - - 0.00 0.00 0.02 0.05
Non-Cash Adjustments To Reconcile Net Income		 - - 8.70 0.85 1.21 1.29 2.02 4.51 5.29 6.88 8.76
Changes in Operating Assets and Liabilities, net		 0.34 0.81 -7.50 0.93 -0.28 -0.34 1.40 0.04 -0.19 2.92 -3.86
Net Cash From Investing Activities		 -2.00 0.00 13 -5.13 5.04 -0.02 0.00 0.00 -0.02 -22 6.11
Net Cash From Continuing Investing Activities		 -2.00 0.00 13 -5.13 5.04 -0.02 0.00 0.00 -0.02 -22 6.11
Purchase of Property, Plant & Equipment		 - - - -0.05 -0.05 -0.02 0.00 0.00 -0.02 0.00 -0.00
Purchase of Investments		 - - - -5.54 -0.03 - - 0.00 0.00 -48 -25
Sale and/or Maturity of Investments		 - - - 0.45 5.11 - - 0.00 0.00 26 31
Other Investing Activities, net		 -2.00 - 13 - - - - - 0.00 0.00 0.00
Net Cash From Financing Activities		 2.41 0.15 2.00 20 17 33 37 19 15 49 52
Net Cash From Continuing Financing Activities		 2.41 0.15 2.00 20 17 33 37 19 15 49 52
Repayment of Debt		 -0.27 - - - - 0.00 0.00 0.00 0.00 -18 5.00
Repurchase of Common Equity		 - - - 0.00 0.00 -0.05 0.00 0.00 0.00 0.00 0.00
Issuance of Debt		 2.68 0.15 - 12 12 0.00 15 0.00 0.00 9.81 0.00
Issuance of Common Equity		 - - 2.01 6.24 0.79 29 21 19 15 56 45
Other Financing Activities, net		 - - 0.01 1.32 4.20 3.23 0.34 -0.02 0.01 0.57 1.39
Effect of Exchange Rate Changes		 - - - - - 0.00 - 0.00 -0.00 0.00 0.00

Quarterly Cash Flow Statements for Achieve Life Sciences

This table details how cash moves in and out of Achieve Life Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -4.37 51 -52 -5.21 3.21 0.26 39 -20 -11 7.36 14
Net Cash From Operating Activities		 -4.36 -5.29 -4.92 -10 -9.19 -11 -9.07 -11 -18 -6.93 -11
Net Cash From Continuing Operating Activities		 -4.36 -5.29 -4.92 -10 -9.19 -11 -9.07 -11 -18 -6.93 -17
Net Income / (Loss) Continuing Operations		 -5.48 -6.49 -8.46 -13 -12 -13 -13 -14 -15 -10 -75
Consolidated Net Income / (Loss)		 -5.48 -6.49 -8.46 -13 -12 -13 -13 -14 -15 -10 -75
Depreciation Expense		 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.05 0.06 0.06 0.06
Amortization Expense		 - 0.00 - 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02
Non-Cash Adjustments To Reconcile Net Income		 0.43 1.77 2.03 1.84 1.24 2.23 2.89 2.34 1.30 -0.69 57
Changes in Operating Assets and Liabilities, net		 0.63 -0.62 1.45 0.23 1.86 -0.57 0.69 0.70 -4.69 3.85 0.17
Net Cash From Investing Activities		 -0.01 0.00 -47 13 12 11 6.70 -13 0.71 14 -138
Net Cash From Continuing Investing Activities		 -0.01 0.00 -47 13 12 11 6.70 -13 0.71 14 -138
Purchase of Property, Plant & Equipment		 -0.01 0.00 - - - 0.00 - - -0.00 0.00 -0.02
Purchase of Investments		 - 0.00 -47 -0.39 -0.93 -3.36 -0.90 -15 -5.09 -1.16 -139
Sale and/or Maturity of Investments		 - 0.00 - 14 13 15 7.60 2.75 5.80 15 1.20
Net Cash From Financing Activities		 - 56 -0.15 -8.11 0.68 0.00 41 4.04 6.26 0.02 168
Net Cash From Continuing Financing Activities		 - 56 -0.15 -8.11 0.68 0.00 41 4.04 6.26 0.02 168
Issuance of Common Equity		 -0.03 56 -0.04 0.18 - 0.00 - 3.92 -0.00 0.00 168
Other Financing Activities, net		 0.03 - - - 0.68 0.00 - 0.12 1.27 0.02 0.06

Annual Balance Sheets for Achieve Life Sciences

This table presents Achieve Life Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 58 3.81 9.89 19 21 40 48 30 19 39 42
Total Current Assets		 57 0.02 5.91 16 17 37 45 27 17 36 40
Cash & Equivalents		 34 0.02 5.28 9.52 17 36 43 25 16 13 21
Short-Term Investments		 21 - - 5.09 - - - - 0.00 22 15
Prepaid Expenses		 1.99 0.00 0.39 0.93 0.67 1.12 1.42 2.45 1.33 2.11 3.49
Other Current Assets		 - - - - - 0.00 0.15 0.11 0.11 0.00 0.00
Plant, Property, & Equipment, net		 0.60 0.00 0.06 0.04 0.06 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.31 3.79 3.93 3.51 3.69 3.32 2.92 2.64 2.39 2.17 1.90
Goodwill		 - 1.03 1.03 1.03 1.03 1.03 1.03 1.03 1.03 1.03 1.03
Intangible Assets		 - 2.76 2.53 2.31 2.09 1.86 1.64 1.42 1.20 0.97 0.75
Other Noncurrent Operating Assets		 0.04 - 0.31 0.12 0.52 0.43 0.25 0.19 0.16 0.16 0.12
Total Liabilities & Shareholders' Equity		 58 3.81 9.89 19 21 40 48 30 19 39 42
Total Liabilities		 21 3.20 2.01 3.28 3.03 3.01 19 22 21 18 20
Total Current Liabilities		 21 3.07 2.01 3.27 2.87 2.94 4.55 22 21 6.68 9.08
Short-Term Debt		 0.05 - 0.03 - - - 0.00 16 17 0.00 5.26
Accounts Payable		 1.34 0.92 0.21 0.14 0.86 0.33 0.84 1.66 0.62 1.95 0.87
Accrued Expenses		 11 2.15 1.32 1.95 0.69 1.04 1.70 2.13 0.63 1.65 0.97
Current Employee Benefit Liabilities		 1.27 - 0.46 1.17 1.12 1.47 1.94 1.68 2.31 3.03 1.92
Other Current Liabilities		 2.36 - - 0.01 0.20 0.09 0.07 0.06 0.06 0.06 0.06
Total Noncurrent Liabilities		 0.11 0.12 0.00 0.01 0.16 0.08 15 0.07 0.01 11 11
Long-Term Debt		 - - - - - - 15 0.00 0.00 9.84 11
Other Noncurrent Operating Liabilities		 - - - 0.01 0.16 0.08 0.00 0.07 0.01 1.22 0.01
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 37 0.61 7.88 16 18 37 28 8.30 -1.45 21 22
Total Preferred & Common Equity		 37 0.61 7.88 16 18 37 28 8.30 -1.45 21 22
Preferred Stock		 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 37 0.61 7.88 16 18 37 28 8.30 -1.45 21 22
Common Stock		 212 2.67 21 41 64 98 122 144 164 226 282
Retained Earnings		 -177 -2.06 -13 -25 -46 -60 -94 -136 -166 -206 -260
Accumulated Other Comprehensive Income / (Loss)		 2.63 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.01

Quarterly Balance Sheets for Achieve Life Sciences

This table presents Achieve Life Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 24 70 65 48 27 59 52 33 190
Total Current Assets		 22 68 63 46 25 57 50 31 188
Cash & Equivalents		 20 66 15 9.54 13 52 32 28 48
Short-Term Investments		 - - 47 33 10 3.52 16 1.19 139
Prepaid Expenses		 1.90 1.31 1.21 2.62 1.76 1.51 1.94 1.79 0.99
Other Current Assets		 0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 2.44 2.32 2.27 2.39 2.36 2.03 1.99 2.04 2.15
Goodwill		 1.03 1.03 1.03 1.03 1.03 1.03 1.03 1.03 1.03
Intangible Assets		 1.25 1.14 1.09 1.03 0.92 0.86 0.81 0.70 0.81
Other Noncurrent Operating Assets		 0.15 0.15 0.15 0.32 0.41 0.14 0.14 0.31 0.30
Total Liabilities & Shareholders' Equity		 24 70 65 48 27 59 52 33 190
Total Liabilities		 20 21 23 17 17 17 18 22 205
Total Current Liabilities		 4.08 21 14 6.72 7.13 8.57 9.73 12 198
Short-Term Debt		 0.00 17 8.80 0.00 1.19 2.55 2.65 5.58 8.83
Accounts Payable		 0.64 0.37 0.55 1.01 1.66 1.22 1.94 0.83 0.61
Accrued Expenses		 1.68 1.56 2.33 2.64 3.26 3.19 2.65 3.19 1.87
Current Employee Benefit Liabilities		 1.70 0.86 1.35 2.34 0.96 1.56 2.43 2.18 2.94
Other Current Liabilities		 0.06 0.63 0.67 0.72 0.06 0.06 0.06 0.05 183
Total Noncurrent Liabilities		 16 0.00 8.80 9.82 9.95 8.69 8.70 11 7.46
Long-Term Debt		 16 0.00 8.80 9.82 8.66 8.66 8.67 9.32 7.46
Other Noncurrent Operating Liabilities		 0.02 0.00 0.00 0.00 1.29 0.04 0.02 1.27 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 4.04 49 42 31 10 42 34 11 -15
Total Preferred & Common Equity		 4.04 49 42 31 10 42 34 11 -15
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 4.04 49 42 31 10 42 34 11 -15
Common Stock		 164 222 223 225 229 273 279 281 331
Retained Earnings		 -160 -172 -181 -193 -218 -231 -246 -270 -345
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.00 -0.01 0.08 0.01 0.00 0.01 0.00 -0.09

Annual Metrics And Ratios for Achieve Life Sciences

This table displays calculated financial ratios and metrics derived from Achieve Life Sciences' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 29,804,273.00 30,020,294.00 11,947,676.00 6,721,103.00 8,352,764.00 3,617,664.00 9,453,542.00 9,710,747.00 21,165,760.00 34,389,946.00 53,233,988.00
DEI Adjusted Shares Outstanding		 13,547.00 13,646.00 59,738.00 336,055.00 417,638.00 3,617,664.00 9,453,542.00 9,710,747.00 21,165,760.00 34,389,946.00 53,233,988.00
DEI Earnings Per Adjusted Shares Outstanding		 -1,240.20 -90.43 -177.16 -37.75 -39.26 -4.07 -3.51 -4.36 -1.41 -1.16 -1.03
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -33.03% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 35.59% 90.97% -782.71% 5.96% -29.70% 10.83% -126.34% -23.10% 31.99% -43.21% -39.46%
EBIT Growth		 35.60% 89.73% -685.67% 5.84% -28.83% 10.66% -124.13% -22.89% 31.83% -42.94% -39.29%
NOPAT Growth		 36.36% 90.86% -286.93% -93.20% -28.99% 10.76% -124.37% -23.29% 31.92% -42.88% -38.27%
Net Income Growth		 35.97% 92.66% -757.62% -19.88% -29.23% 10.16% -125.06% -27.74% 29.60% -33.58% -37.21%
EPS Growth		 55.86% 92.66% -757.62% -19.88% -29.23% 86.37% 24.72% 1.96% 62.50% 17.33% -0.81%
Operating Cash Flow Growth		 97.98% 42.29% -4,408.42% -16.65% -43.24% 11.45% -118.49% -27.61% 34.84% -21.61% -66.16%
Free Cash Flow Firm Growth		 -55.47% -137.82% 67.45% -21.41% -51.38% 11.36% -107.95% -30.22% 29.00% -19.59% -81.95%
Invested Capital Growth		 -37.40% 103.33% 294.96% -51.15% 16.38% 7.26% -104.19% -561.67% 149.37% -1,948.98% 143.05%
Revenue Q/Q Growth		 2.09% -100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 18.66% 88.22% -2,413.72% 1.76% 4.23% -9.82% -7.90% -9.89% 17.63% -24.37% -4.16%
EBIT Q/Q Growth		 18.91% 86.49% -2,466.73% 0.24% 2.92% -11.49% -7.83% -9.83% 17.53% -24.23% -4.13%
NOPAT Q/Q Growth		 14.53% 88.33% -199.77% 0.56% 2.94% -11.42% -7.80% -10.11% 17.64% -24.64% -3.33%
Net Income Q/Q Growth		 19.07% 90.20% -479.73% 0.81% 2.63% -11.59% -7.90% -10.66% 16.18% -20.90% -4.40%
EPS Q/Q Growth		 12.33% 90.20% -479.73% 0.81% 2.63% -35.16% -25.54% -1.27% 26.47% -12.73% 10.07%
Operating Cash Flow Q/Q Growth		 93.47% 90.26% -64.21% 0.77% 0.83% 6.48% -10.25% -18.72% 21.69% -19.34% -21.60%
Free Cash Flow Firm Q/Q Growth		 -1,982.71% 32.95% -7.21% -2.49% -1.01% 11.55% -10.32% -21.87% 20.84% -18.23% -22.10%
Invested Capital Q/Q Growth		 34.38% 107.27% -3.53% 15.38% 86.59% -55.66% -104.32% 71.44% -37.58% -111.93% 149.09%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -92.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -103.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -93.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -92.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 71.00% 77.62% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.30% 100.00% 99.85% 98.67% 98.97% 99.53% 99.95% 103.90% 107.30% 100.27% 98.78%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -47.00% -6.49% -249.33% -107.15% -96.86% -53.24% -101.49% -233.04% -869.88% -409.51% -257.67%
Cash Return on Invested Capital (CROIC)		 0.00% -3,303.50% -434.46% -444.09% -946.67% -752.76% 0.00% 0.00% -10,223.27% 0.00% -2,794.87%
Operating Return on Assets (OROA)		 -29.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -29.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -47.00% -6.49% -249.33% -107.15% -96.86% -53.24% -101.49% -233.04% -869.88% -409.51% -257.67%
Return on Equity Simple (ROE_SIMPLE)		 -44.87% -202.30% -134.32% -80.29% -90.83% -39.51% -118.22% -510.06% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -1.20 -4.64 -8.97 -12 -10 -23 -29 -19 -28 -38
NOPAT Margin		 -72.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -7.18% -0.12% -214.31% -36.84% -30.77% -16.76% -31.23% -74.94% -293.95% -105.28% -72.98%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -117.17% -123.52% -90.39% -101.19%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 65.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 138.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 203.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -17 -1.74 -14 -13 -17 -15 -33 -41 -28 -40 -55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -1.52 -13 -13 -16 -15 -33 -41 -28 -39 -55
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.96 24.60 2.04 0.51 0.25 0.79 2.62 2.87 0.00 5.79 12.30
Price to Tangible Book Value (P/TBV)		 0.96 0.00 3.72 0.65 0.30 0.85 2.90 4.07 0.00 6.41 13.41
Price to Revenue (P/Rev)		 1.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 25.20 4.50 0.00 0.00 0.00 0.00 0.00 453.30 0.00 156.80
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.53 1.94 -11.87 0.47 0.76
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.53 0.00 0.00 0.47 0.52
Financial Leverage		 -1.43 -1.45 -0.65 -0.85 -0.93 -0.95 -0.98 -1.01 -1.03 -1.18 -1.05
Leverage Ratio		 1.60 1.63 1.61 1.22 1.19 1.11 1.34 2.13 7.20 2.98 1.90
Compound Leverage Factor		 1.59 1.63 1.61 1.21 1.17 1.10 1.34 2.22 7.72 2.99 1.87
Debt to Total Capital		 0.42% 0.00% 0.34% 0.00% 0.00% 0.00% 34.73% 65.94% 109.20% 32.00% 43.32%
Short-Term Debt to Total Capital		 0.14% 0.00% 0.34% 0.00% 0.00% 0.00% 0.00% 65.94% 109.20% 0.00% 13.86%
Long-Term Debt to Total Capital		 0.28% 0.00% 0.00% 0.00% 0.00% 0.00% 34.73% 0.00% 0.00% 32.00% 29.46%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.58% 100.00% 99.66% 100.00% 100.00% 100.00% 65.27% 34.07% -9.20% 68.00% 56.68%
Debt to EBITDA		 -0.01 0.00 0.00 0.00 0.00 0.00 -0.45 -0.40 -0.62 -0.25 -0.30
Net Debt to EBITDA		 3.28 0.00 0.41 0.00 0.00 0.00 0.85 0.21 -0.06 0.62 0.36
Long-Term Debt to EBITDA		 -0.01 0.00 0.00 0.00 0.00 0.00 -0.45 0.00 0.00 -0.25 -0.20
Debt to NOPAT		 -0.01 0.00 -0.01 0.00 0.00 0.00 -0.64 -0.56 -0.88 -0.35 -0.43
Net Debt to NOPAT		 4.19 0.00 1.18 0.00 0.00 0.00 1.21 0.30 -0.08 0.88 0.52
Long-Term Debt to NOPAT		 -0.01 0.00 0.00 0.00 0.00 0.00 -0.64 0.00 0.00 -0.35 -0.29
Altman Z-Score		 -3.10 -0.41 -1.10 -1.83 -3.93 3.54 -1.78 -9.95 -14.44 -5.82 -4.37
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.77 0.01 2.93 4.75 6.04 12.60 9.80 1.27 0.82 5.46 4.39
Quick Ratio		 2.68 0.00 2.63 4.47 5.81 12.22 9.46 1.15 0.75 5.14 4.01
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -8.27 -20 -6.40 -7.77 -12 -10 -22 -28 -20 -24 -44
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% -29,508.33% -28,709.43% -79,258.82% 0.00% 0.00% -116,566.67% 0.00% -1,236,625.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -15.78 -7.02 -9.73 -53.24
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -21.00 -8.58 -12.09 -60.40
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -21.00 -8.59 -12.09 -60.40
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 6.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 42.28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 57.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 57.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -18 0.60 2.35 1.15 1.34 1.43 -0.06 -0.40 0.20 -3.62 1.56
Invested Capital Turnover		 -1.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -4.86 18 1.76 -1.20 0.19 0.10 -1.49 -0.34 0.59 -3.82 5.18
Enterprise Value (EV)		 -19 15 11 -6.47 -12 -6.55 45 15 89 97 245
Market Capitalization		 36 15 16 8.13 4.43 29 74 24 87 121 265
Book Value per Share		 $1.26 $0.02 $0.66 $2.35 $2.16 $10.31 $2.97 $0.86 ($0.07) $0.61 $0.40
Tangible Book Value per Share		 $1.26 ($0.11) $0.36 $1.85 $1.79 $9.51 $2.68 $0.60 ($0.17) $0.55 $0.37
Total Capital		 38 0.61 7.91 16 18 37 43 24 16 31 38
Total Debt		 0.16 0.00 0.03 0.00 0.00 0.00 15 16 17 9.84 16
Total Long-Term Debt		 0.11 0.00 0.00 0.00 0.00 0.00 15 0.00 0.00 9.84 11
Net Debt		 -55 -0.02 -5.48 -15 -17 -36 -28 -8.70 1.64 -25 -20
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.04 0.05 0.02 0.00 0.00 0.02 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -19 -3.07 -1.58 -2.34 -2.20 -1.81 -2.98 -2.97 -2.19 -4.58 -0.34
Debt-free Net Working Capital (DFNWC)		 37 -3.06 3.92 12 14 34 40 22 13 30 36
Net Working Capital (NWC)		 37 -3.06 3.90 12 14 34 40 5.73 -3.83 30 31
Net Nonoperating Expense (NNE)		 3.67 0.03 5.94 3.72 4.83 4.41 9.99 14 10 12 16
Net Nonoperating Obligations (NNO)		 -55 -0.02 -5.53 -15 -17 -36 -28 -8.70 1.64 -25 -20
Total Depreciation and Amortization (D&A)		 0.14 0.22 0.28 0.28 0.25 0.26 0.25 0.24 0.23 0.25 0.28
Debt-free, Cash-free Net Working Capital to Revenue		 -101.87% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 202.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 201.73% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1,408.00) ($1,474.00) ($442.00) ($72.20) ($39.80) $0.00 $0.00 ($4.00) ($1.50) ($1.24) ($1.25)
Adjusted Weighted Average Basic Shares Outstanding		 13.55K 13.68K 63.74K 336.06K 1.57M 0.00 0.00 10.59M 19.83M 32.07M 43.59M
Adjusted Diluted Earnings per Share		 ($1,408.00) ($1,474.00) ($442.00) ($72.20) ($39.80) $0.00 $0.00 ($4.00) ($1.50) ($1.24) ($1.25)
Adjusted Weighted Average Diluted Shares Outstanding		 13.55K 13.68K 63.74K 336.06K 1.57M 0.00 0.00 10.59M 19.83M 32.07M 43.59M
Adjusted Basic & Diluted Earnings per Share		 ($1,408.00) ($1,474.00) ($442.00) ($72.20) ($39.80) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 11.89K 13.61K 23.97K 175.51K 412.32K 0.00 0.00 17.93M 34.25M 34.69M 53.24M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -1.20 -4.64 -8.97 -12 -10 -23 -29 -19 -27 -38
Normalized NOPAT Margin		 -72.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -92.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -22.78 -9.74 -16.13 -67.55
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -15.96 -6.82 -11.28 -46.91
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -22.78 -9.75 -16.13 -67.56
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -15.96 -6.82 -11.28 -46.91
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.33% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Achieve Life Sciences

This table displays calculated financial ratios and metrics derived from Achieve Life Sciences' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 21,165,760.00 34,251,911.00 34,341,303.00 34,341,303.00 34,389,946.00 34,685,072.00 34,685,072.00 51,104,968.00 53,233,988.00 53,239,988.00 102,659,057.00
DEI Adjusted Shares Outstanding		 21,165,760.00 34,251,911.00 34,341,303.00 34,341,303.00 34,389,946.00 34,685,072.00 34,685,072.00 51,104,968.00 53,233,988.00 53,239,988.00 102,659,057.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.26 -0.19 -0.25 -0.36 -0.36 -0.37 -0.37 -0.28 -0.28 -0.19 -0.73
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 54.93% 29.70% -10.02% -90.94% -159.77% -115.09% -50.01% -18.17% -17.47% 21.46% -499.90%
EBIT Growth		 54.67% 29.51% -9.97% -90.26% -158.22% -114.32% -49.81% -18.08% -17.34% 21.39% -497.28%
NOPAT Growth		 54.76% 29.66% -9.29% -89.68% -159.65% -113.69% -50.16% -18.71% -13.86% 18.85% -45.28%
Net Income Growth		 51.25% 27.78% -2.69% -76.03% -125.71% -97.52% -50.31% -15.42% -18.62% 20.73% -487.90%
EPS Growth		 70.13% 48.00% 41.86% -5.88% -60.87% -42.31% -48.00% 22.22% 37.84% 48.65% -116.22%
Operating Cash Flow Growth		 60.84% 36.31% 26.29% -101.95% -110.56% -109.68% -84.29% -9.25% -95.64% 37.48% -18.83%
Free Cash Flow Firm Growth		 44.50% 31.71% 36.68% -6.31% -26.74% -38.54% -88.10% -32.65% -200.39% -18.16% 2,295.92%
Invested Capital Growth		 149.37% -33.67% -495.54% -644.59% -1,948.98% -1,665.33% -77.96% -85.85% 143.05% -18.46% -7,248.44%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 25.89% -23.80% -40.74% -47.87% -0.83% -2.51% 1.85% -16.49% -0.23% 31.47% -649.72%
EBIT Q/Q Growth		 25.68% -23.52% -40.35% -47.66% -0.87% -2.52% 1.89% -16.38% -0.24% 31.32% -645.44%
NOPAT Q/Q Growth		 25.23% -22.79% -39.72% -47.86% -2.35% -1.06% 1.81% -16.89% 1.82% 27.98% -75.78%
Net Income Q/Q Growth		 22.96% -18.59% -30.29% -47.88% 1.21% -3.78% 0.85% -13.55% -1.53% 30.65% -635.34%
EPS Q/Q Growth		 32.35% -13.04% 3.85% -44.00% -2.78% 0.00% 0.00% 24.32% 17.86% 17.39% -321.05%
Operating Cash Flow Q/Q Growth		 15.03% -21.17% 6.94% -110.77% 11.41% -20.67% 18.21% -24.94% -58.65% 61.44% -55.47%
Free Cash Flow Firm Q/Q Growth		 36.03% -2.23% 0.00% -62.57% 23.74% -11.75% -35.77% -14.64% -72.69% 56.04% 2,623.20%
Invested Capital Q/Q Growth		 -37.58% 1.53% -813.57% -20.42% -111.93% 14.05% 18.88% -25.76% 149.09% -336.54% -4,932.38%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 111.82% 107.36% 99.66% 99.81% 97.75% 98.94% 99.99% 97.55% 98.81% 99.77% 98.42%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -869.88% -109.49% -105.95% -186.03% -409.51% -154.55% -120.11% -161.08% -257.67% -496.15% -844.99%
Cash Return on Invested Capital (CROIC)		 -10,223.27% -7,039.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,794.87% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -869.88% -109.49% -105.95% -186.03% -409.51% -154.55% -120.11% -161.08% -257.67% -496.15% -844.99%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -55.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.44 -4.22 -5.90 -8.73 -8.93 -9.03 -8.86 -10 -10 -7.32 -13
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -57.72% -9.19% -9.65% -20.57% -29.97% -12.13% -8.77% -11.68% -20.20% -20.49% -57.52%
Return On Investment Capital (ROIC_SIMPLE)		 -21.85% -6.34% -9.85% -21.18% -29.06% -44.84% -16.76% -23.05% -26.79% -28.63% -800.65%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.90 -6.05 -8.49 -13 -13 -13 -13 -15 -15 -10 -76
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.84 -5.99 -8.43 -12 -13 -13 -13 -15 -15 -10 -76
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 3.15 3.82 5.19 5.79 9.01 1.88 4.79 12.30 14.66 0.00
Price to Tangible Book Value (P/TBV)		 0.00 3.29 4.02 5.55 6.41 11.12 1.97 5.07 13.41 17.49 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 453.30 534.76 0.00 0.00 0.00 0.00 0.00 0.00 156.80 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.51
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -11.87 0.35 0.42 0.31 0.47 0.96 0.27 0.34 0.76 1.40 -1.11
Long-Term Debt to Equity		 0.00 0.00 0.21 0.31 0.47 0.84 0.21 0.26 0.52 0.87 -0.51
Financial Leverage		 -1.03 -0.99 -1.02 -1.04 -1.18 -1.05 -1.05 -1.08 -1.05 -1.32 -7.97
Leverage Ratio		 7.20 1.82 1.80 2.04 2.98 1.63 1.47 1.54 1.90 2.89 9.24
Compound Leverage Factor		 8.05 1.95 1.80 2.04 2.91 1.61 1.47 1.50 1.87 2.88 9.09
Debt to Total Capital		 109.20% 25.74% 29.40% 23.84% 32.00% 48.94% 21.19% 25.19% 43.32% 58.25% 1,012.69%
Short-Term Debt to Total Capital		 109.20% 25.74% 14.70% 0.00% 0.00% 5.93% 4.81% 5.89% 13.86% 21.81% 548.88%
Long-Term Debt to Total Capital		 0.00% 0.00% 14.70% 23.84% 32.00% 43.01% 16.37% 19.30% 29.46% 36.44% 463.81%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -9.20% 74.26% 70.60% 76.16% 68.00% 51.06% 78.81% 74.81% 56.68% 41.75% -912.69%
Debt to EBITDA		 -0.62 -0.68 -0.68 -0.31 -0.25 -0.21 -0.22 -0.21 -0.30 -0.29 -0.14
Net Debt to EBITDA		 -0.06 1.97 1.69 1.04 0.62 0.29 0.87 0.70 0.36 0.27 1.48
Long-Term Debt to EBITDA		 0.00 0.00 -0.34 -0.31 -0.25 -0.19 -0.17 -0.16 -0.20 -0.18 -0.06
Debt to NOPAT		 -0.88 -0.97 -0.97 -0.44 -0.35 -0.30 -0.32 -0.30 -0.43 -0.41 -0.40
Net Debt to NOPAT		 -0.08 2.79 2.41 1.48 0.88 0.41 1.24 0.99 0.52 0.39 4.20
Long-Term Debt to NOPAT		 0.00 0.00 -0.48 -0.44 -0.35 -0.27 -0.24 -0.23 -0.29 -0.25 -0.18
Altman Z-Score		 -10.54 1.62 0.87 0.37 -3.51 -8.70 -2.49 -1.37 -1.17 -7.57 -1.95
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.82 3.29 4.56 6.78 5.46 3.51 6.64 5.14 4.39 2.62 0.95
Quick Ratio		 0.75 3.23 4.47 6.39 5.14 3.26 6.46 4.94 4.01 2.47 0.95
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.03 -4.12 -4.12 -6.70 -5.11 -5.71 -7.76 -8.89 -15 -6.75 170
Operating Cash Flow to CapEx		 -72,733.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -449,425.00% 0.00% -67,356.25%
Free Cash Flow to Firm to Interest Expense		 -5.12 -5.07 -5.13 -10.33 -25.95 -30.87 -40.60 -46.31 -61.17 -24.63 614.78
Operating Cash Flow to Interest Expense		 -5.55 -6.50 -6.12 -15.98 -46.64 -59.94 -47.48 -59.02 -71.62 -25.30 -38.91
Operating Cash Flow Less CapEx to Interest Expense		 -5.55 -6.50 -6.12 -15.98 -46.64 -59.94 -47.48 -59.02 -71.64 -25.30 -38.96
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.20 0.20 -1.42 -1.71 -3.62 -3.12 -2.53 -3.18 1.56 -3.69 -186
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.59 -0.10 -1.78 -2.02 -3.82 -3.31 -1.11 -1.47 5.18 -0.58 -183
Enterprise Value (EV)		 89 106 118 130 97 79 34 124 245 142 499
Market Capitalization		 87 156 161 163 121 93 78 161 265 157 670
Book Value per Share		 ($0.07) $1.44 $1.23 $0.91 $0.61 $0.30 $1.20 $0.66 $0.40 $0.20 ($0.14)
Tangible Book Value per Share		 ($0.17) $1.38 $1.17 $0.85 $0.55 $0.24 $1.15 $0.62 $0.37 $0.17 ($0.16)
Total Capital		 16 67 60 41 31 20 53 45 38 26 1.61
Total Debt		 17 17 18 9.82 9.84 9.85 11 11 16 15 16
Total Long-Term Debt		 0.00 0.00 8.80 9.82 9.84 8.66 8.66 8.67 11 9.32 7.46
Net Debt		 1.64 -49 -44 -33 -25 -13 -44 -37 -20 -14 -171
Capital Expenditures (CapEx)		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.19 -2.12 -3.69 -4.10 -4.58 -4.18 -4.52 -5.14 -0.34 -4.46 -188
Debt-free Net Working Capital (DFNWC)		 13 64 58 39 30 19 51 43 36 25 -0.54
Net Working Capital (NWC)		 -3.83 47 49 39 30 18 48 40 31 19 -9.36
Net Nonoperating Expense (NNE)		 2.04 2.27 2.56 3.79 3.43 3.80 3.86 4.08 4.49 2.84 62
Net Nonoperating Obligations (NNO)		 1.64 -49 -44 -33 -25 -13 -44 -37 -20 -14 -171
Total Depreciation and Amortization (D&A)		 0.06 0.06 0.06 0.07 0.07 0.08 0.07 0.07 0.07 0.07 0.08
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.23) ($0.26) ($0.25) ($0.36) ($0.37) ($0.37) ($0.37) ($0.28) ($0.23) ($0.19) ($0.80)
Adjusted Weighted Average Basic Shares Outstanding		 19.83M 25.05M 34.32M 34.36M 32.07M 34.69M 34.69M 51.02M 43.59M 53.38M 93.51M
Adjusted Diluted Earnings per Share		 ($0.23) ($0.26) ($0.25) ($0.36) ($0.37) ($0.37) ($0.37) ($0.28) ($0.23) ($0.19) ($0.80)
Adjusted Weighted Average Diluted Shares Outstanding		 19.83M 25.05M 34.32M 34.36M 32.07M 34.69M 34.69M 51.02M 43.59M 53.38M 93.51M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 34.25M 34.34M 34.34M 34.39M 34.69M 34.69M 51.10M 53.23M 53.24M 102.66M 102.90M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.07 -4.19 -5.90 -8.73 -8.93 -9.03 -8.79 -10 -10 -7.32 -13
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -6.22 -7.44 -10.56 -19.32 -64.19 -70.08 -66.59 -77.10 -59.12 -37.19 -274.25
NOPAT to Interest Expense		 -4.37 -5.20 -7.34 -13.45 -45.34 -48.79 -46.40 -53.95 -40.52 -26.73 -46.48
EBIT Less CapEx to Interest Expense		 -6.23 -7.44 -10.56 -19.32 -64.19 -70.08 -66.59 -77.10 -59.13 -37.19 -274.31
NOPAT Less CapEx to Interest Expense		 -4.38 -5.20 -7.34 -13.45 -45.34 -48.79 -46.40 -53.95 -40.53 -26.73 -46.54
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Achieve Life Sciences (NASDAQ: ACHV) remains a development-stage company with no reported revenue in the periods provided. Its financial profile is dominated by research and development spending, recurring operating losses, cash burn and reliance on equity financing.

Liquidity improved substantially during the second quarter of 2026. Cash and equivalents increased to $48.0 million from $28.1 million in Q1, while short-term investments rose to $139.3 million from $1.2 million. However, this improvement was primarily driven by a $168.5 million financing inflow, including $168.4 million from common-stock issuance, rather than by operating activities.

Operating performance weakened in Q2 2026. Operating expenses increased to $18.4 million from $10.5 million in Q1, led by higher SG&A and research and development costs. The company reported a $74.8 million net loss, heavily affected by $57.6 million of net other expense. The cash-flow statement shows a $17.1 million continuing operating cash outflow, or $10.8 million including discontinued or other operating activity classifications. Achieve also ended the quarter with negative shareholders’ equity of $14.7 million, largely reflecting accumulated losses and a sharp increase in other current liabilities.

  • Liquidity increased sharply: Cash and short-term investments totaled approximately $187.0 million at June 30, 2026, compared with roughly $29.3 million at March 31, 2026.
  • Interest and investment income is becoming more meaningful: Q2 2026 interest and investment income reached $1.5 million, up from $297,000 in Q1, helping partially offset operating costs.
  • Financing provided near-term funding: The $168.4 million common-equity issuance materially strengthened the cash position and may support clinical development and commercialization activities.
  • Cash flow benefited from large noncash adjustments: Q2 included $57.5 million of noncash adjustments, so the $74.8 million net loss materially overstated the quarter’s cash operating loss; investors should determine the nature and persistence of these adjustments.
  • Investment balances fluctuate considerably: Short-term investments have ranged from approximately $1.2 million to $161.8 million across the reported balance-sheet periods, indicating active movement between cash and investment holdings.
  • Revenue remains absent: Achieve reported zero revenue in each income statement provided, leaving the company dependent on financing and cash reserves rather than operating sales.
  • Losses remain substantial: Q2 2026 operating loss was $18.4 million, compared with $10.5 million in Q1 and $14.5 million in Q4 2025. The quarterly net loss expanded to $74.8 million because of significant net other expense.
  • Operating cash burn continues: Net cash used in operating activities was $10.8 million in Q2 2026, following outflows of $6.9 million in Q1, $18.0 million in Q4 2025 and $11.3 million in Q3 2025.
  • Shareholder dilution is a major risk: The Q2 equity raise increased common stock outstanding and weighted-average basic shares to approximately 93.5 million, compared with 53.4 million in Q1 and 43.6 million in Q4 2025.
  • The balance sheet has deteriorated: Total liabilities rose to $205.1 million from $22.4 million in Q1, driven primarily by $183.4 million of other current liabilities, while total equity turned negative at $14.7 million.
10/10/26 03:07 AM ETAI Generated. May Contain Errors.

Achieve Life Sciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Achieve Life Sciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Achieve Life Sciences' net income appears to be on a downward trend, with a most recent value of -$54.65 million in 2025, falling from -$16.80 million in 2015. The previous period was -$39.83 million in 2024. Find out what analysts predict for Achieve Life Sciences in the coming months.

Achieve Life Sciences' total operating income in 2025 was -$54.88 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $54.88 million

Over the last 10 years, Achieve Life Sciences' total revenue changed from $18.16 million in 2015 to $0.00 in 2025, a change of -100.0%.

In the past 11 quarters, Achieve Life Sciences' cash and equivalents has ranged from $9.54 million in Q3 2024 to $66.40 million in Q1 2024, and is currently $47.96 million as of their latest financial filing in Q2 2026.

Achieve Life Sciences had total debt of $16.45 million at the end of 2025, a 67.2% increase from 2024, and a 10,375.2% increase since 2015.

Over the last 10 years, Achieve Life Sciences' book value per share changed from 1.26 in 2015 to 0.40 in 2025, a change of -67.8%.


Related Companies

Financial statements for NASDAQ:ACHV last updated on 8/11/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
The only 5 stocks that matter
SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...
TradeSmith | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A simple options setup that cuts through the noise
Ian Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...
TradeWins | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel